O	0	8	Efficacy
O	9	11	of
B-intervention	12	24	prophylactic
I-intervention	25	35	antibiotic
O	36	50	administration
O	51	54	for
O	55	61	breast
O	62	68	cancer
O	69	76	surgery
O	77	79	in
O	80	90	overweight
O	91	93	or
O	94	99	obese
O	100	108	patients
O	108	109	:
O	110	111	a
O	112	122	randomized
O	123	133	controlled
O	134	139	trial
O	139	140	.

O	141	143	To
O	144	150	assess
O	151	154	the
O	155	161	impact
O	162	164	of
O	165	177	prophylactic
O	178	189	antibiotics
O	190	192	on
O	193	196	the
O	197	207	prevention
O	208	210	of
B-condition	211	219	surgical
I-condition	220	224	site
I-condition	225	234	infection
I-condition	235	236	(
I-condition	236	239	SSI
I-condition	239	240	)
O	241	244	and
O	245	248	the
O	249	253	cost
O	253	254	-
O	254	267	effectiveness
O	268	270	of
O	271	275	this
O	276	287	prophylaxis
O	288	291	for
O	292	298	breast
O	299	305	cancer
O	306	313	surgery
O	314	316	in
O	317	327	overweight
O	328	330	or
O	331	336	obese
O	337	342	women
O	342	343	.

O	344	347	SSI
O	348	350	is
O	351	357	higher
O	358	362	than
O	363	371	expected
O	372	377	after
O	378	384	breast
O	385	392	surgery
O	392	393	.

O	394	401	Obesity
O	402	405	was
O	406	411	found
O	412	414	to
O	415	417	be
O	418	421	one
O	422	424	of
O	425	428	the
O	429	433	risk
O	434	441	factors
O	441	442	.

O	443	446	The
O	447	452	trial
O	453	456	was
O	457	465	designed
O	466	468	as
O	469	470	a
O	471	476	phase
O	477	479	IV
O	480	490	randomized
O	490	491	,
O	492	502	controlled
O	502	503	,
O	504	512	parallel
O	512	513	-
O	513	518	group
O	519	527	efficacy
O	528	533	trial
O	533	534	.

O	535	537	It
O	538	541	was
O	542	551	conducted
O	552	554	at
O	555	556	a
O	557	565	tertiary
O	566	576	university
O	577	585	hospital
O	585	586	.

B-eligibility	587	597	Overweight
I-eligibility	598	600	or
I-eligibility	601	606	obese
I-eligibility	607	612	women
I-eligibility	613	617	with
I-eligibility	618	628	clinically
I-eligibility	629	634	early
I-eligibility	634	635	-
I-eligibility	635	640	stage
I-eligibility	641	647	breast
I-eligibility	648	654	cancer
I-eligibility	655	658	who
I-eligibility	659	662	had
I-eligibility	663	667	been
I-eligibility	668	676	assigned
I-eligibility	677	679	to
I-eligibility	680	687	undergo
I-eligibility	688	695	surgery
O	696	700	were
O	701	709	eligible
O	709	710	.

O	711	719	Patients
O	720	724	were
O	725	733	randomly
O	734	743	allocated
O	744	746	to
O	747	753	either
O	754	755	a
O	756	767	prophylaxis
O	768	770	or
O	771	772	a
O	773	780	control
O	781	786	group
O	787	789	by
O	790	795	using
O	796	797	a
O	798	806	computer
O	806	807	-
O	807	816	generated
O	817	821	list
O	821	822	.

O	823	826	The
O	827	838	prophylaxis
O	839	844	group
O	845	853	received
O	854	855	1
O	856	857	g
O	858	868	ampicillin
O	868	869	-
O	869	878	sulbactam
O	879	892	intravenously
O	893	895	at
O	896	906	anesthesia
O	906	907	.

O	908	911	The
O	912	919	control
O	920	925	group
O	926	934	received
O	935	937	no
O	938	950	intervention
O	950	951	.

O	952	960	Patients
O	961	964	and
O	965	974	observers
O	975	979	were
O	980	987	blinded
O	988	990	to
O	991	994	the
O	995	1006	assignments
O	1006	1007	.

O	1008	1011	The
O	1012	1019	primary
O	1020	1027	outcome
O	1028	1031	was
O	1032	1035	the
O	1036	1046	comparison
O	1047	1049	of
B-outcome-Measure	1050	1053	SSI
I-outcome-Measure	1054	1064	incidences
O	1065	1067	of
O	1068	1071	the
O	1072	1073	2
O	1074	1080	groups
O	1080	1081	.

O	1082	1090	Patients
O	1091	1095	were
O	1096	1105	monitored
O	1106	1109	for
O	1110	1112	30
O	1113	1117	days
O	1117	1118	.

O	1119	1120	A
O	1121	1126	total
O	1127	1129	of
B-total-participants	1130	1133	369
O	1134	1142	patients
O	1143	1147	were
O	1148	1156	included
O	1157	1159	in
O	1160	1165	final
O	1166	1174	analysis
O	1174	1175	,
O	1176	1179	out
O	1180	1182	of
O	1183	1188	which
B-intervention-participants	1189	1192	187
O	1193	1197	were
O	1198	1207	allocated
O	1208	1211	for
O	1212	1223	prophylaxis
O	1224	1227	and
B-control-participants	1228	1231	182
O	1232	1236	were
O	1237	1245	randomly
O	1246	1254	assigned
O	1255	1257	to
O	1258	1261	the
B-control	1262	1269	control
I-control	1270	1275	group
O	1275	1276	.

O	1277	1285	Analysis
O	1286	1289	was
O	1290	1294	done
O	1295	1304	according
O	1305	1307	to
O	1308	1311	the
O	1312	1321	intention
O	1321	1322	-
O	1322	1324	to
O	1324	1325	-
O	1325	1330	treat
O	1331	1340	principle
O	1340	1341	.

O	1342	1353	Prophylaxis
O	1354	1367	significantly
O	1368	1375	reduced
O	1376	1379	the
B-outcome	1380	1383	SSI
I-outcome	1384	1388	rate
O	1389	1390	(
B-iv-bin-percent	1390	1391	4
I-iv-bin-percent	1391	1392	.
I-iv-bin-percent	1392	1393	8
I-iv-bin-percent	1393	1394	%
O	1394	1395	)
O	1396	1398	in
O	1399	1402	the
O	1403	1414	prophylaxis
O	1415	1420	group
O	1421	1425	when
O	1426	1434	compared
O	1435	1439	with
O	1440	1444	that
O	1445	1447	in
O	1448	1451	the
O	1452	1459	control
O	1460	1465	group
O	1466	1467	[
B-cv-bin-percent	1467	1469	13
I-cv-bin-percent	1469	1470	.
I-cv-bin-percent	1470	1471	7
I-cv-bin-percent	1471	1472	%
O	1472	1473	;
O	1474	1482	relative
O	1483	1487	risk
O	1488	1489	(
O	1489	1491	RR
O	1491	1492	)
O	1493	1494	0
O	1494	1495	.
O	1495	1497	35
O	1497	1498	;
O	1499	1501	95
O	1501	1502	%
O	1503	1505	CI
O	1505	1506	:
O	1507	1508	0
O	1508	1509	.
O	1509	1511	17
O	1511	1512	-
O	1512	1513	0
O	1513	1514	.
O	1514	1516	73
O	1516	1517	]
O	1517	1518	.

O	1519	1521	No
B-outcome	1522	1529	adverse
I-outcome	1530	1538	reaction
O	1539	1542	was
O	1543	1551	observed
O	1551	1552	.

O	1553	1556	The
B-outcome	1557	1561	mean
I-outcome	1562	1565	SSI
I-outcome	1565	1566	-
I-outcome	1566	1573	related
I-outcome	1574	1578	cost
B-cv-cont-mean	1579	1580	(
I-cv-cont-mean	1580	1582	20
I-cv-cont-mean	1582	1583	.
I-cv-cont-mean	1583	1585	26
I-cv-cont-mean	1586	1589	USD
O	1589	1590	)
O	1591	1594	was
O	1595	1600	found
O	1601	1603	to
O	1604	1606	be
O	1607	1620	significantly
O	1621	1627	higher
O	1628	1630	in
O	1631	1634	the
O	1635	1642	control
O	1643	1648	group
O	1649	1653	when
O	1654	1662	compared
O	1663	1667	with
O	1668	1672	that
O	1673	1674	(
B-iv-cont-mean	1674	1675	8
I-iv-cont-mean	1675	1676	.
I-iv-cont-mean	1676	1678	48
I-iv-cont-mean	1679	1682	USD
O	1682	1683	)
O	1684	1686	in
O	1687	1690	the
O	1691	1702	prophylaxis
O	1703	1708	group
O	1708	1709	.

O	1710	1720	Antibiotic
O	1721	1732	prophylaxis
O	1733	1746	significantly
O	1747	1756	decreased
O	1757	1760	SSI
O	1761	1770	incidence
O	1771	1776	after
O	1777	1785	elective
O	1786	1793	surgery
O	1794	1797	and
O	1798	1801	was
O	1802	1807	shown
O	1808	1810	to
O	1811	1813	be
O	1814	1818	cost
O	1818	1819	-
O	1819	1828	effective
O	1829	1831	in
O	1832	1837	obese
O	1838	1844	breast
O	1845	1851	cancer
O	1852	1860	patients
O	1860	1861	.

O	1862	1876	ClinicalTrials
O	1876	1877	.
O	1877	1880	gov
O	1881	1891	Identifier
O	1891	1892	:
O	1893	1904	NCT00356148
O	1904	1905	.
